Life Science Investing Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Life Science Investing "LEQEMBI®" IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
Life Science Investing Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
Life Science Investing Biogen Receives European Commission Approval for ZURZUVAE® , the First and Only Treatment Approved for Women with Postpartum Depression in Europe
Life Science Investing Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers
pharmaceutical investing Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke
AEG Confirms Pre-Sale of 35% of Initial 8 MW UAE Capacity with Strong Revenue Outlook and Clear Expansion Path
AFDG - Embracing US strategy, acquisition of Butembo copper deposit in the DRC. Copper added to draft list of US strategic minerals
